Ultime notizie per K33 (OTC:ARCNF) Azioni

K33 AB is a holding company with broad exposure to the digital assets industry. The Company offers market execution, actionable insights, and superior support to private and institutional partners across EMEA.

K33 AB

Marriott International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) shares are<a href="https://www.benzinga.com/movers"> trading higher on Tuesday </a>after the first-quarter FY25 earnings.
The company reported<a href="https://www.benzinga.com/pressreleases/25/05/n45217056/marriott-international-reports-first-quarter-2025-results"> first-quarter 2025 sales growth </a>of 4.7% year-on-year to $6.26 billion. It beat the analyst consensus estimate of $6.17 billion.
Comparable systemwide constant dollar RevPAR increased (compared to the first quarter of FY24): 
<ul>
<li>4.1% worldwide</li>
<li>3.3% in the U.S. and Canada, and </li>
<li>5.9% in international markets.</li>
</ul>
The company added roughly 12,200 net rooms during the quarter, a 4.6% increase from the end of Q1 2024.
Total expenses increased 4.2% Y/Y to $5.3 billion. Adjusted EBITDA for the quarter was $1.22 billion versus $1.14 billion a year ago.
Also Read: <a href="https://www.benzinga.com/news/25/04/45040811/marriott-bets-355m-on-trendy-citizenm-hotels-to-woo-modern-travelers">Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers</a>
Operating margin for the quarter expanded 50 basis points to 15.1%, with operating income increasing 8% to $948 million.
Adjusted EPS of $2.32 <a href="https://www.benzinga.com/earnings">beat the consensus</a> estimate of $2.25.
At the end of the quarter, Marriott&#8217;s global system totaled nearly 9,500 properties, with approximately 1,719,000 rooms. Marriott held $500 million in cash and equivalents as of March 31.
In the first quarter of 2025, Marriott repurchased 2.8 million shares of common stock for $800 million. Year to date, through April 29, the company has returned over $1.2 billion to shareholders through dividends and share repurchases.
&#8220;The combination of continued travel demand, the strength of our brands and our fee driven business model drove strong financial results in the first quarter,&#8221; said President and CEO Anthony Capuano.
Outlook: Marriott reaffirmed 2025 adjusted EPS outlook of $9.82 – $10.19 versus the $10.11 estimate and Gross fee revenue of $5.365 billion &#8211; $5.475 billion..
The company expects second-quarter adjusted EPS of $2.57-$2.62 against an estimate of $2.68 and gross fee revenue of $1.38 billion &#8211; $1.39 billion.
Price Action: Marriott shares traded higher by 2.1% at $252.47 at last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45194848/footwear-giant-skechers-to-go-private-in-more-than-9b-deal-with-3g-capital-stock-surges">Footwear Giant Skechers To Go Private At 30% Premium In PE Deal</a></li>
</ul>
Image: Shutterstock

News

Travel

General

Marriott Stock Spikes After Hospitality Giant Tops Forecasts, Returns $1.2B To Shareholders

Citigroup analyst Spiro Dounis maintains ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) with a Buy and lowers the price target from $110 to $102.

Price Target

Analyst Ratings

Citigroup Maintains Buy on ONEOK, Lowers Price Target to $102

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and raises the price target from $11 to $13.

Reiteration

BCRX

RBC Capital Reiterates Outperform on BioCryst Pharma, Raises Price Target to $13

Citigroup analyst Ashwin Shirvaikar maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Buy and lowers the price target from $98 to $95.

PYPL

Citigroup Maintains Buy on PayPal Holdings, Lowers Price Target to $95

Florida Governor Ron DeSantis has signed a new law that imposes sweeping restrictions on the ballot initiative process, a move that could have direct implications for the state's ongoing efforts to legalize <a href="https://www.benzinga.com/cannabis">adult-use marijuana</a> and expand Medicaid.
The law, signed Friday, requires organizers of citizen-led ballot measures to post a $1 million bond before collecting signatures, prohibits out-of-state and noncitizen petitioners and shortens the timeframe for submitting petitions to elections officials. It also bars individuals with felony convictions from participating unless their voting rights are restored and mandates that petition signers provide personal identification details, such as a driver&#8217;s license or the last four digits of their Social Security number.
As reported by <a class="" href="https://www.marijuanamoment.net/with-florida-marijuana-legalization-measure-circulating-desantis-signs-bill-making-it-harder-to-qualify-ballot-initiatives/">Marijuana Moment</a>, the bill's sponsor, Rep. Jenna Persons-Mulicka (R), said the initiative process has been "taken over by out-of-state fraudsters looking to make a quick buck and by special interests intent on buying their way into our Constitution." Governor DeSantis echoed that sentiment on social media, saying the bill would "combat petition fraud and prevent the special interest-abuse of our constitutional amendment process."
Critics argue the legislation will make it prohibitively difficult for grassroots efforts to qualify initiatives for the ballot. State Sen. Carlos Smith (D) <a href="https://apnews.com/article/florida-citizens-ballot-initiative-constitutional-amendment-desantis-50a5ac0048825c0756c7b850d4b81fed">told</a> the Associated Press the measure was "intentionally designed to make it impossible for any statewide citizen initiative to make it to the ballot ever again," calling it "the final kill shot against direct democracy."
Among the most immediately impacted is Smart &amp; Safe Florida, the campaign seeking to place a revised adult-use marijuana legalization measure on the 2026 ballot. The group has already been fined over $120,000 by the state for allegedly submitting petitions beyond the required 30-day window and was recently issued a cease-and-desist letter. The case has been referred to the Florida Department of Law Enforcement for a potential criminal investigation.
Smart &amp; Safe Florida has not publicly commented on how the new law may affect its campaign but previously stated that legal counsel vetted its documents and procedures. "The claims made appear to be a targeted effort to thwart the ability for the people of Florida to express their support of a citizen-driven amendment," the campaign said in a statement to Marijuana Moment. "We stand by the process and&#8230;look forward to challenging the validity of these claims."
In 2024, Smart &amp; Safe Florida raised more than $150 million to support its effort, largely from leading cannabis operators. Donors include:
<ul>
<li>Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>), the largest donor, by far.</li>
<li>Verano Holdings Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>).</li>
<li>Curaleaf Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>).</li>
<li>Green Thumb Industries Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>).</li>
<li>AYR Wellness Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>).</li>
<li>Cresco Labs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>).</li>
</ul>
The campaign's 2024 initiative fell short of the 60% supermajority required to pass a constitutional amendment in Florida, but organizers are preparing for another run in 2026.
Federal Lawsuit Challenges Constitutionality Of New Law
Following the news, a federal lawsuit was filed to challenge the new restrictions. As reported by <a class="" href="https://apnews.com/article/florida-constitutional-amendment-ballot-voters-desantis-fc1df2612ebf8b9c4dd275eb89d67482">The Associated Press</a>, Florida Decides Healthcare, a campaign supporting Medicaid expansion, brought the case along with the Southern Poverty Law Center and the Elias Law Group.
"This bill is not about improving the ballot initiative process. It attacks the fundamental freedom of Floridians to participate in their own democracy," said FDH executive director Mitch Emerson. He noted that new legal risks and logistical hurdles have already caused some volunteers to withdraw, adding that the new compliance burden could raise campaign costs by millions.
Under the law, anyone collecting more than 25 signed petitions beyond their own or immediate family members must register with the state or face felony charges. Campaigns will also face higher fines for submitting petitions late or to the wrong county.
Florida has a history of using ballot initiatives to enact major reforms, including the legalization of medical marijuana, the restoration of voting rights for people with felony convictions and a minimum wage increase. But in recent years, Republican lawmakers have sought to tighten the rules around constitutional amendments.
Former state Sen. Jeff Brandes, a Republican and leader of the nonprofit Florida Policy Project, wrote that it should be "difficult to change the constitution, but not impossible." He added, "Unless you're the Florida Legislature… then you just keep moving the goalpost until only you can score."
Photo: Shutterstock

Cannabis

Regulations

Politics

AYRWF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

VRNOF

DeSantis Signs New Petition Law That Could Block Marijuana Ballot Campaign—Lawsuit Challenges Constitutionality

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $462 to $464.

VRTX

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $464

Citigroup analyst Kyle Menges maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Buy and raises the price target from $95 to $105.

Citigroup Maintains Buy on Oshkosh, Raises Price Target to $105

Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are trading lower on Tuesday after the company reported <a href="https://www.benzinga.com//node/45208000">first-quarter earnings </a>on Monday.
Despite beating consensus estimates, the stock may be facing pressure amid elevated investor expectations. Shares of Palantir have climbed 409% over the past year and 44% year-to-date.
The Details: Palantir reported adjusted earnings per share of 13 cents, inline with the consensus estimate. In addition, the company reported sales of $883.86 million, beating the consensus estimate of $862.83 million and representing a 39% year-over-year increase.
Palantir reported a total U.S. commercial contract value of $810 million, with remaining deal value totaling $2.32 billion.
The company&#8217;s customer count increased 39% year-over-year.
&#8220;Our Rule of 40 score increased to&nbsp;83%&nbsp;in the last quarter, once again breaking the metric. We are in the middle of a tectonic shift in the adoption of our software, particularly in the U.S. where our revenue soared&nbsp;55%&nbsp;year-over-year, while our U.S. commercial revenue expanded&nbsp;71%&nbsp;year-over-year in the&nbsp;first quarter&nbsp;to surpass a one-billion-dollar annual run rate,&#8221; said Alexander C. Karp, co-founder and CEO of Palantir Technologies. 
Outlook: The company raised its guidance for fiscal-year 2025 sales. It now sees sales from $3.89 billion to $3.90 billion, versus the consensus estimate of $3.75 billion. It previously expected earnings from $3.74 billion to $3.76 billion.
For the second-quarter, the company sees sales from $934 million to 938 million, versus the consensus estimate of $899.12 million.
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>Mizuho analyst Matthew Broome maintained an Underperform rating on Palantir and raised the price target from&nbsp;$80&nbsp;to&nbsp;$94.</li>
<li>Cantor Fitzgerald analyst Thomas Blakey maintained a Neutral rating on Palantir and raised the price target from&nbsp;$98&nbsp;to&nbsp;$110.</li>
<li>UBS analyst Karl Keirstead maintained a Neutral rating on Palantir and raised the price target from&nbsp;$105&nbsp;to&nbsp;$110.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/25/05/45220993/jittery-senate-republicans-urge-ustr-to-unveil-trade-deals-one-by-one-after-trumps-recession-comment-we-dont-necessarily-have-a-lot-of-tolerance-for-pain">Jittery Senate Republicans Urge USTR To Unveil Trade Deals One By One After Trump&#8217;s Recession Comment: &#8216;We Don&#8217;t Necessarily Have A Lot Of Tolerance For Pain&#8217;</a>
PLTR Price Action: At the time of writing, Palantir shares are trading 12.8% lower at $107.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

PLTR

Palantir Stock Is Tumbling Tuesday Despite Beating Q1 Estimates: What's Going On?

Morgan Stanley analyst Alex Straton maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and lowers the price target from $63 to $62.

URBN

Morgan Stanley Maintains Overweight on Urban Outfitters, Lowers Price Target to $62

Morgan Stanley maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Equal-Weight and lowers the price target from $56 to $50.

PRKS

Morgan Stanley Maintains Equal-Weight on United Parks & Resorts, Lowers Price Target to $50

WIIM

LMND

LMND stock has given up its prior gain. Lemonade shares were trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and lowers the price target from $145 to $140.

BNTX

Citigroup Maintains Buy on BioNTech, Lowers Price Target to $140

Citigroup analyst Ronald Josey maintains Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Neutral and lowers the price target from $19 to $18.

UPWK

Citigroup Maintains Neutral on Upwork, Lowers Price Target to $18

Morgan Stanley analyst Alexandra Steiger maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Overweight and lowers the price target from $136 to $133.

Morgan Stanley Maintains Overweight on TJX Companies, Lowers Price Target to $133

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) has outperformed the market over the past 5 years by 3.93% on an annualized basis producing an average annual return of 17.87%. Currently, MetLife has a market capitalization of $51.25 billion. 
Buying $1000 In MET: If an investor had bought $1000 of MET stock 5 years ago, it would be worth $2,194.21 today based on a price of $76.22 for MET at the time of writing.
<h3>MetLife's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746546312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning MetLife Stock In The Last 5 Years

BMEA

Biomea Fusion shares are trading lower after the company reported worse-than-expected Q1 EPS results. HC Wainwright maintained a Buy rating on the stock but lowered its price target from $40 to $18.

Morgan Stanley analyst Michael Cyprys maintains T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Equal-Weight and raises the price target from $94 to $95.

TROW

Morgan Stanley Maintains Equal-Weight on T. Rowe Price Group, Raises Price Target to $95

Upwork Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) delivered strong first-quarter results and investors are driving the stock higher on Tuesday. Analysts are weighing in on the company's <a href="https://www.benzinga.com/news/earnings/25/05/45207747/upwork-stock-rallies-after-better-than-expected-q1-raised-fy25-eps-guidance">strong report. </a>
Q1 Results: Upwork beat analysts' estimates on the top and bottom lines with earnings of 34 cents per and revenue of $192.71 million for the quarter.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a>
Expert Ideas: Analysts from Goldman Sachs and Needham both highlighted Upwork's 25% year-over-year increase in AI-related work, strong engagement with its AI assistant Uma and the successful launch of Business Plus, which led to a sequential improvement in GSV. 
Goldman Sachs pointed to the 3% growth in GSV per active client and the 11% gain for large clients as a &#8220;solid start to 2025,&#8221; even amid the current macroeconomic pressures. 
Both firms attributed Upwork's adjusted EBITDA beat to lower-than-expected expenditure on sales and marketing (S&amp;M). However, they cautioned that the Q1 EBITDA margin of 29% will be the high point for 2025, as reinvestments in AI and Enterprise will weigh on the metric going forward. 
Goldman Sachs and Needham revised their 2026 estimates down slightly due to continued macro uncertainty.&nbsp;
Analyst Updates: Goldman Sachs analyst Eric Sheridan maintained Upwork with a Buy rating and a price target of $25. Needham analyst Bernie McTernan reiterated a Buy rating and a $19 price target on the stock. 
UPWK Stock Price Action: Upwork shares were up 21.5% at $16.19 at the time of publication, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Tech

Upwork Delivers 'Solid Start To 2025': Analyst

Citigroup analyst Daniel Grosslight maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Sell and raises the price target from $25 to $30.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Citigroup Maintains Sell on Hims & Hers Health, Raises Price Target to $30

Morgan Stanley analyst Thomas Yeh maintains Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Overweight and lowers the price target from $58 to $47.

Comments

K33

Notizie

Ultime notizie per K33 (OTC:ARCNF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO